Penile TPF
Disease site: Urological
Treatment Modality: Chemotherapy
Status: In active follow-up
Penile TPF is a Phase II trial of docetaxel, cisplatin and 5-fluorouracil chemotherapy in locally advanced and metastatic carcinoma of the penis. The primary objective is to determine the activity of combination docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in cancer of the penis.
A total of 29 patients, with histologically-proven squamous cell carcinoma of the penis, were recruited. Patients entered onto the trial received three courses of TPF chemotherapy.
The primary endpoint is overall response rate (complete remission rate + partial remission rate). The secondary endpoints are to determine the proportion of patients with inoperable locoregional disease rendered operable following TPF, to evaluate safety and tolerability, and to assess progression-free and overall survival.
Chief Investigator: | Dr Amit Bahl, Bristol Haematology & Oncology Centre. |
Co-Chief Investigator: | Dr Steve Nicholson, University Hospitals of Leicester
|
Sponsor: | University Hospitals Bristol NHS Foundation Trust and The Institute of Cancer Research |
Source of funding: | Cancer Research UK
|
ISRCTN: | 78108737
|
In the Clinical Trials Section
